Search clinical trials for: RP101

Total 27 results

Ivix LLX

Completed

Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Hypoactive Sexual Desire Disorder (HSDD)

Russian Federation
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
Ivix LLX

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

Hypoactive Sexual Desire Disorder(HSDD)

Russian Federation
Universidad Complutense de Madrid

Recruiting

Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home (PROBELDERLY)

Covid19

Spain
Ivix LLX

Completed

BP101 for Adults With Female Sexual Dysfunction

Female Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexual Desire Disorder

Russian Federation
Finch Research and Development LLC.

Withdrawn

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) (SPROUT)

Autism Spectrum Disorder | Autism | ASD | FMT | Fecal Transplant | Autistic Thinking | Autistic Behavior | Fecal Microbiota Transplant | Finch | CP101 | SPROUT
University Hospital, Angers

Unknown

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Huntington's Disease

France
NuPathe Inc.

Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months (NP101-009)

Migraine Disorders

United States
Innervate Radiopharmaceuticals LLC (Formerly: Illumina...
Memorial Sloan Kettering Cancer Center; New Approaches to Neuroblastoma Therapy...

Active, not recruiting

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Neuroblastoma

United States
NuPathe Inc.

Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months (NP101-008)

Migraine Disorders

United States
Innervate Radiopharmaceuticals LLC (Formerly: Illumina...
Icahn School of Medicine at Mount Sinai

Recruiting

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

Cardiovascular Diseases

United States
NuPathe Inc.

Completed

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (NP101-007)

Migraine Disorders

United States
Finch Research and Development LLC.

Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff (PRISM3)

Clostridium Difficile Infection Recurrence

Canada, United States
Redwood Pharma AB
Cross Research S.A.

Completed

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Dry Eye Syndromes

Austria, Germany, Hungary
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Horizon Pharma USA, Inc.

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (MITO-001)

Inherited Mitochondrial Disease, Including Leigh Syndrome

United States
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
SciClone Pharmaceuticals

Terminated

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine (RP101)

Pancreatic Cancer

United States, Chile, Spain, Brazil, Argentina, France, Germany, Hungary, Netherlands, Peru, Poland, Romania, United Kingdom
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
NuPathe Inc.

Completed

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

Compare Bioequivalence Patches Previously Used in the NP101-007 Study

United States
NuPathe Inc.

Completed

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Acute Migraine
NuPathe Inc.

Completed

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period (NP101-011)

Migraine Disorders

United States
NuPathe Inc.

Completed

Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers (NP101-006)

Migraine Disorders

United States

3

Subscribe